Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.

https://www.thehindubusinessline.com/companies/natco-pharma-launches-generic-semaglutide-injection-in-india/article70764288.ece Copy Natco Pharma has launched the ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

The Democratic Party continues to lead over Republicans in the battle to control the House of Representatives, but by a slimmer margin than two months ago. The latest Rasmussen Reports national ...

The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the ...

(Bloomberg) -- Indian drugmakers seized on the patent expiry for Novo Nordisk A/S’s blockbuster weight-loss and diabetes medication to roll out cut-price generic versions in a nation with the ...